-
1
-
-
2342466734
-
Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030
-
Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27, 1047-1053.
-
(2004)
Diabetes Care
, vol.27
, pp. 1047-1053
-
-
Wild, S.1
Roglic, G.2
Green, A.3
Sicree, R.4
King, H.5
-
2
-
-
9444244529
-
Gastric inhibitory polypeptide and glucagon-like peptide- 1 in the pathogenesis of type 2 diabetes
-
Nauck, M. A.; Baller, B.; Meier, J. J. Gastric inhibitory polypeptide and glucagon-like peptide- 1 in the pathogenesis of type 2 diabetes. Diabetes 2004, 53(Suppl. 3), S190-S196.
-
(2004)
Diabetes
, vol.53
, Issue.SUPPL. 3
-
-
Nauck, M.A.1
Baller, B.2
Meier, J.J.3
-
3
-
-
0030831056
-
Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes
-
Avignon, A.; Radauceanu, A.; Monnier, L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997, 20, 1822-1826.
-
(1997)
Diabetes Care
, vol.20
, pp. 1822-1826
-
-
Avignon, A.1
Radauceanu, A.2
Monnier, L.3
-
4
-
-
12944320328
-
Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study
-
Balkau, B.; Hu, G.; Qiao, Q.; Tuomilehto, J.; Borch-Johnsen, K.; Pyorala, K. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 2004, 47, 2118-2128.
-
(2004)
Diabetologia
, vol.47
, pp. 2118-2128
-
-
Balkau, B.1
Hu, G.2
Qiao, Q.3
Tuomilehto, J.4
Borch-Johnsen, K.5
Pyorala, K.6
-
5
-
-
4544232468
-
Inhibitors of dipeptidyl peptidase IV: A novel approach for the prevention and treatment of type 2 diabetes?
-
Deacon, C. F.; Ahren, B.; Holst, J. J. Inhibitors of dipeptidyl peptidase IV: A novel approach for the prevention and treatment of type 2 diabetes? Expert Opin. Invest. Drugs 2004, 13, 1091-1102.
-
(2004)
Expert Opin. Invest. Drugs
, vol.13
, pp. 1091-1102
-
-
Deacon, C.F.1
Ahren, B.2
Holst, J.J.3
-
6
-
-
0034967893
-
The entero-insular axis in type 2 diabetes - Incretins as therapeutic agents
-
Creutzfeldt, W. The entero-insular axis in type 2 diabetes - incretins as therapeutic agents. Exp. Clin. Endocrinol. Diabetes 2001, 109(Suppl. 2), S288-S303.
-
(2001)
Exp. Clin. Endocrinol. Diabetes
, vol.109
, Issue.SUPPL. 2
-
-
Creutzfeldt, W.1
-
8
-
-
0028953577
-
Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
-
Deacon, C. F.; Johnsen, A. H.; Holst, J. J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metabol. 1995, 80, 952-957.
-
(1995)
J. Clin. Endocrinol. Metabol.
, vol.80
, pp. 952-957
-
-
Deacon, C.F.1
Johnsen, A.H.2
Holst, J.J.3
-
9
-
-
11244266087
-
CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model
-
Kruschinski, C.; Skripuletz, T.; Bedoui, S.; Tschernig, T.; Pabst, R.; Nassenstein, C.; Braun, A.; Von Horsten, S. CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model. Clin. Exp. Immunol. 2005, 139, 17-24.
-
(2005)
Clin. Exp. Immunol.
, vol.139
, pp. 17-24
-
-
Kruschinski, C.1
Skripuletz, T.2
Bedoui, S.3
Tschernig, T.4
Pabst, R.5
Nassenstein, C.6
Braun, A.7
Von Horsten, S.8
-
10
-
-
0038759066
-
Deficiency of CD26 results in a change of cytokine and immunoglobin secretion after stimulation by pokeweed mitogen
-
Yan, S.; Marguet, D.; Dobers, J.; Reutter, W.; Fan, H. Deficiency of CD26 results in a change of cytokine and immunoglobin secretion after stimulation by pokeweed mitogen. Eur. J. Immunol. 2003, 33, 1519-1527.
-
(2003)
Eur. J. Immunol.
, vol.33
, pp. 1519-1527
-
-
Yan, S.1
Marguet, D.2
Dobers, J.3
Reutter, W.4
Fan, H.5
-
11
-
-
0034811909
-
Improved Glucose Tolerance via Enhanced Glucose-Dependent Insulin Secretion in Dipeptidyl Peptidase IV-Deficient Fischer Rats
-
Nagakura, T.; Yasuda, N.; Yamazaki, K.; Ikuta, H.; Yoshikawa, S.; Asano, O.; Tanaka, I. Improved Glucose Tolerance via Enhanced Glucose-Dependent Insulin Secretion in Dipeptidyl Peptidase IV-Deficient Fischer Rats. Biochem. Biophys. Res. Comm. 2001, 284, 501-506.
-
(2001)
Biochem. Biophys. Res. Comm.
, vol.284
, pp. 501-506
-
-
Nagakura, T.1
Yasuda, N.2
Yamazaki, K.3
Ikuta, H.4
Yoshikawa, S.5
Asano, O.6
Tanaka, I.7
-
12
-
-
0037974604
-
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
-
Conarello, S. L.; Li, Z.; Ronan, J.; Roy, R. S.; Zhu, L.; Jiang, G.; Liu, F.; Woods, J.; Zycband, E.; Moller, D. E.; Thornberry, N. A.; Zhang, B. B. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 6825-6830.
-
(2003)
Proc. Natl. Acad. Sci. U. S. A.
, vol.100
, pp. 6825-6830
-
-
Conarello, S.L.1
Li, Z.2
Ronan, J.3
Roy, R.S.4
Zhu, L.5
Jiang, G.6
Liu, F.7
Woods, J.8
Zycband, E.9
Moller, D.E.10
Thornberry, N.A.11
Zhang, B.B.12
-
13
-
-
4344675057
-
Therapeutic strategies based on glucagon-like peptide 1
-
Deacon, C. F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004, 53, 2181-2189.
-
(2004)
Diabetes
, vol.53
, pp. 2181-2189
-
-
Deacon, C.F.1
-
14
-
-
9444285818
-
Twelveand 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
-
Ahren, B.; Gomis, R.; Standl, E.; Mills, D.; Schweizer, A. Twelveand 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27, 2874-2880.
-
(2004)
Diabetes Care
, vol.27
, pp. 2874-2880
-
-
Ahren, B.1
Gomis, R.2
Standl, E.3
Mills, D.4
Schweizer, A.5
-
15
-
-
2442482515
-
Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes
-
Ahren, B.; Landin-Olsson, M.; Jansson, P.-A.; Svensson, M.; Holmes, D.; Schweizer, A. Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2004, 89, 2078-2084.
-
(2004)
J. Clin. Endocrinol. Metab.
, vol.89
, pp. 2078-2084
-
-
Ahren, B.1
Landin-Olsson, M.2
Jansson, P.-A.3
Svensson, M.4
Holmes, D.5
Schweizer, A.6
-
16
-
-
23044487247
-
Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
-
Ahren, B.; Pacini, G.; Foley, J. E.; Schweizer, A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005, 28, 1936-1940.
-
(2005)
Diabetes Care
, vol.28
, pp. 1936-1940
-
-
Ahren, B.1
Pacini, G.2
Foley, J.E.3
Schweizer, A.4
-
17
-
-
0037787851
-
Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV
-
Lambeir, A.-M.; Durinx, C.; Scharpe, S.; De Meester, I. Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 2003, 40, 209-294.
-
(2003)
Crit. Rev. Clin. Lab. Sci.
, vol.40
, pp. 209-294
-
-
Lambeir, A.-M.1
Durinx, C.2
Scharpe, S.3
De Meester, I.4
-
18
-
-
25844459084
-
Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes: Potential Importance of Selectivity Over Dipeptidyl Peptidases 8 and 9
-
Lankas, G. R.; Leiting, B.; Roy, R. S.; Eiermann, G. J.; Beconi, M.G.; Biftu, T.; Chan, C.-C.; Edmondson, S.; Feeney, W. P.; He, H.; Ippolito, D. E.; Kim, D.; Lyons, K. A.; Ok, H. O.; Patel, R. A.; Petrov, A. N.; Pryor, K. A.; Qian, X.; Reigle, L.; Woods, A.; Wu, J. K.; Zaller, D.; Zhang, X.; Zhu, L.; Weber, A. E.; Thornberry, N. A. Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes: Potential Importance of Selectivity Over Dipeptidyl Peptidases 8 and 9. Diabetes 2005, 54, 2988-2994.
-
(2005)
Diabetes
, vol.54
, pp. 2988-2994
-
-
Lankas, G.R.1
Leiting, B.2
Roy, R.S.3
Eiermann, G.J.4
Beconi, M.G.5
Biftu, T.6
Chan, C.-C.7
Edmondson, S.8
Feeney, W.P.9
He, H.10
Ippolito, D.E.11
Kim, D.12
Lyons, K.A.13
Ok, H.O.14
Patel, R.A.15
Petrov, A.N.16
Pryor, K.A.17
Qian, X.18
Reigle, L.19
Woods, A.20
Wu, J.K.21
Zaller, D.22
Zhang, X.23
Zhu, L.24
Weber, A.E.25
Thornberry, N.A.26
more..
-
19
-
-
19944427998
-
(2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4, 3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
-
Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Roy, R. S.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4, 3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. J. Med. Chem. 2005, 48, 141-151.
-
(2005)
J. Med. Chem.
, vol.48
, pp. 141-151
-
-
Kim, D.1
Wang, L.2
Beconi, M.3
Eiermann, G.J.4
Fisher, M.H.5
He, H.6
Hickey, G.J.7
Kowalchick, J.E.8
Leiting, B.9
Lyons, K.10
Marsilio, F.11
McCann, M.E.12
Patel, R.A.13
Petrov, A.14
Scapin, G.15
Patel, S.B.16
Roy, R.S.17
Wu, J.K.18
Wyvratt, M.J.19
Zhang, B.B.20
Zhu, L.21
Thornberry, N.A.22
Weber, A.E.23
more..
-
20
-
-
22244482444
-
Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome
-
Wiedeman, P. E.; Trevillyan, J. M. Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome. Drug Discov. Today: Therapeutic Strategies 2005, 2, 143-149.
-
(2005)
Drug Discov. Today: Therapeutic Strategies
, vol.2
, pp. 143-149
-
-
Wiedeman, P.E.1
Trevillyan, J.M.2
-
21
-
-
33644892053
-
Inhibitors of Dipeptidyl Peptidase IV - Recent Advances and Structural Views
-
Hunziker, D.; Hennig, M.; Peters, J.-U. Inhibitors of Dipeptidyl Peptidase IV - Recent Advances and Structural Views. Curr. Top. Med. Chem. 2005, 5(16), 1623-1637.
-
(2005)
Curr. Top. Med. Chem.
, vol.5
, Issue.16
, pp. 1623-1637
-
-
Hunziker, D.1
Hennig, M.2
Peters, J.-U.3
-
22
-
-
0037234531
-
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
-
Drucker, J. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin. Invest. Drugs 2003, 12, 87-100.
-
(2003)
Expert Opin. Invest. Drugs
, vol.12
, pp. 87-100
-
-
Drucker, J.1
-
23
-
-
0036228243
-
Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinernia, and beta-cell glucose responsiveness in VDF fa/fa Zucker rats
-
Pospisilik, J. A.; Stafford, S. G.; Demuth, H. U.; Brownsey, R.; Parkhouse, W.; Finegood, D., T.; McIntosh, C. H. S.; Pederson, R. A. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinernia, and beta-cell glucose responsiveness in VDF fa/fa Zucker rats. Diabetes 2002, 51, 943-950.
-
(2002)
Diabetes
, vol.51
, pp. 943-950
-
-
Pospisilik, J.A.1
Stafford, S.G.2
Demuth, H.U.3
Brownsey, R.4
Parkhouse, W.5
Finegood, D.T.6
McIntosh, C.H.S.7
Pederson, R.A.8
-
24
-
-
0000135759
-
Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-I (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
-
Balkan, B.; Kwasnik, L.; Miserendino, R.; Holst, J. J.; Li, X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-I (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999, 42, 1324-1331.
-
(1999)
Diabetologia
, vol.42
, pp. 1324-1331
-
-
Balkan, B.1
Kwasnik, L.2
Miserendino, R.3
Holst, J.J.4
Li, X.5
-
25
-
-
0036312876
-
Chronic inhibition of circulating dipeptidyl peptidase TV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats
-
Sudre, B.; Broqua, P.; White, R. B.; Ashworth, D.; Evans, D. M.; Haigh, R.; Junien, J.-L.; Aubert, M. L. Chronic inhibition of circulating dipeptidyl peptidase TV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes 2002, 51, 1461-1469.
-
(2002)
Diabetes
, vol.51
, pp. 1461-1469
-
-
Sudre, B.1
Broqua, P.2
White, R.B.3
Ashworth, D.4
Evans, D.M.5
Haigh, R.6
Junien, J.-L.7
Aubert, M.L.8
-
26
-
-
0037267892
-
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition
-
Nagakura, T.; Yasuda, N.; Yamazaki, K.; Ikuta, H.; Tanaka, I. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metab., Clin. Exp. 2003, 52, 81-86.
-
(2003)
Metab., Clin. Exp.
, vol.52
, pp. 81-86
-
-
Nagakura, T.1
Yasuda, N.2
Yamazaki, K.3
Ikuta, H.4
Tanaka, I.5
-
27
-
-
33644838045
-
The novel, xanthine-based, DPP-IV inhibitor NN7201 and LAF237 improve glucose tolerance, but do not prevent progression of diabetes in diabetic fatty rats
-
Rolin, N.; Nygaard, H.; Wilken, M.; Karstrup, A. B.; Carr, R. D. The novel, xanthine-based, DPP-IV inhibitor NN7201 and LAF237 improve glucose tolerance, but do not prevent progression of diabetes in diabetic fatty rats. Diabetes 2004, 53, A340.
-
(2004)
Diabetes
, vol.53
-
-
Rolin, N.1
Nygaard, H.2
Wilken, M.3
Karstrup, A.B.4
Carr, R.D.5
-
28
-
-
0036435607
-
Enhanced secretion of glucagon-like peptide 1 by biguanide compounds
-
Yasuda, N.; Inoue, T.; Nagakura, T.; Yamazaki, K.; Kira, K.; Saeki, T.; Tanaka, I. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem. Biophys. Res. Comm. 2002, 298, 779-784.
-
(2002)
Biochem. Biophys. Res. Comm.
, vol.298
, pp. 779-784
-
-
Yasuda, N.1
Inoue, T.2
Nagakura, T.3
Yamazaki, K.4
Kira, K.5
Saeki, T.6
Tanaka, I.7
-
29
-
-
3342908639
-
Metformin Causes Reduction of Food Intake and Body Weight Gain and Improvement of Glucose Intolerance in Combination with Dipeptidyl Peptidase IV Inhibitor in Zucker fa/fa Rats
-
Yasuda, N.; Inoue, T.; Nagakura, T.; Yamazaki, K.; Kira, K.; Saeki, T.; Tanaka, I. Metformin Causes Reduction of Food Intake and Body Weight Gain and Improvement of Glucose Intolerance in Combination with Dipeptidyl Peptidase IV Inhibitor in Zucker fa/fa Rats. J. Pharmacol. Exp. Ther. 2004, 310, 614-619.
-
(2004)
J. Pharmacol. Exp. Ther.
, vol.310
, pp. 614-619
-
-
Yasuda, N.1
Inoue, T.2
Nagakura, T.3
Yamazaki, K.4
Kira, K.5
Saeki, T.6
Tanaka, I.7
-
30
-
-
0036583164
-
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
-
Ahren, B.; Simonsson, E.; Larsson, H.; Landin-Olsson, M.; Torgeirsson, H.; Jansson, P.-A.; Sandqvist, M.; Bavenholm, P.; Efendic, S.; Eriksson, J. W.; Dickinson, S.; Holmes, D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002, 25, 869-875.
-
(2002)
Diabetes Care
, vol.25
, pp. 869-875
-
-
Ahren, B.1
Simonsson, E.2
Larsson, H.3
Landin-Olsson, M.4
Torgeirsson, H.5
Jansson, P.-A.6
Sandqvist, M.7
Bavenholm, P.8
Efendic, S.9
Eriksson, J.W.10
Dickinson, S.11
Holmes, D.12
-
31
-
-
2442482515
-
Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes
-
Ahren, B.; Landin-Olsson, M.; Jansson, P.-A.; Svensson, M.; Holmes, D.; Schweizer, A. Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes J. Clin. Endocrinol. Metab. 2004, 89, 2078-2084.
-
(2004)
J. Clin. Endocrinol. Metab.
, vol.89
, pp. 2078-2084
-
-
Ahren, B.1
Landin-Olsson, M.2
Jansson, P.-A.3
Svensson, M.4
Holmes, D.5
Schweizer, A.6
-
32
-
-
24944446982
-
Evidence for insulin independent suppression of glucagon secretion by LAF237
-
Jones-Leone, A.; Barilla, D.; He, Y.-L.; Ho, Y. Y.; Ligueros-Saylan, M. Evidence for insulin independent suppression of glucagon secretion by LAF237. Diabetologia 2004, suppl. 1, A289.
-
(2004)
Diabetologia
, Issue.SUPPL. 1
-
-
Jones-Leone, A.1
Barilla, D.2
He, Y.-L.3
Ho, Y.Y.4
Ligueros-Saylan, M.5
-
33
-
-
23844463766
-
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed b-cell function in patients with type 2 diabetes
-
Mari, A.; Sallas, W. M.; He, Y. L.; Watson, C.; Ligueros-Saylan, M.; Dunning, B. E.; Deacon, C. F.; Holst, J. J.; Foley, J. E. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed b-cell function in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2005, 90, 4888-4894.
-
(2005)
J. Clin. Endocrinol. Metab.
, vol.90
, pp. 4888-4894
-
-
Mari, A.1
Sallas, W.M.2
He, Y.L.3
Watson, C.4
Ligueros-Saylan, M.5
Dunning, B.E.6
Deacon, C.F.7
Holst, J.J.8
Foley, J.E.9
-
35
-
-
22744449063
-
Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
-
Augeri, D. J.; Robl, J. A.; Betebenner, D. A.; Magnin, D. R.; Khanna, A.; Robertson, J. G.; Wang, A.; Simpkins, L. M.; Taunk,P.; Huang, Q.; Han, S.-P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G. E.; Egan, D. M.; Marcinkeviciene, J.; Chang, S. Y.; Biller, S. A.; Kirby, M. S.; Parker, R. A.; Hamann, L.G. Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48, 5025-5037.
-
(2005)
J. Med. Chem.
, vol.48
, pp. 5025-5037
-
-
Augeri, D.J.1
Robl, J.A.2
Betebenner, D.A.3
Magnin, D.R.4
Khanna, A.5
Robertson, J.G.6
Wang, A.7
Simpkins, L.M.8
Taunk, P.9
Huang, Q.10
Han, S.-P.11
Abboa-Offei, B.12
Cap, M.13
Xin, L.14
Tao, L.15
Tozzo, E.16
Welzel, G.E.17
Egan, D.M.18
Marcinkeviciene, J.19
Chang, S.Y.20
Biller, S.A.21
Kirby, M.S.22
Parker, R.A.23
Hamann, L.G.24
more..
-
37
-
-
33947685633
-
-
Prosidion-Ltd Product Pipeline
-
Prosidion-Ltd Product Pipeline; http.//www.prosidion.com/products/ index.html; 2006.
-
(2006)
-
-
-
38
-
-
14044253388
-
The DP IV-inhibitor P93/01 improves glucose tolerance in humans with HbA1c greater than 6.0
-
Heins, J.; Glund, K.; Hoffmann, T.; Metzner, J.; Demuth, H.-U. The DP IV-inhibitor P93/01 improves glucose tolerance in humans with HbA1c greater than 6.0. Diabetes 2004, 53, A128.
-
(2004)
Diabetes
, vol.53
-
-
Heins, J.1
Glund, K.2
Hoffmann, T.3
Metzner, J.4
Demuth, H.-U.5
-
39
-
-
0027533758
-
Truncated GLP-1 proglucagon 78-107-amide inhibits gastric and pancreatic functions in man
-
Wettergren, A.; Schjoldager, B.; Mortensen, P. E.; Myhre, J.; Christiansen, J.; Holst, J. J. Truncated GLP-1 proglucagon 78-107-amide inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 1993, 38, 665-673.
-
(1993)
Dig. Dis. Sci.
, vol.38
, pp. 665-673
-
-
Wettergren, A.1
Schjoldager, B.2
Mortensen, P.E.3
Myhre, J.4
Christiansen, J.5
Holst, J.J.6
-
40
-
-
0035127228
-
GLP-1 inhibits gastric emptying of water but does not influence plasma vasopressin, sodium, or osmolality
-
Näslund, E.; Bogefors, J.; Grybäck, P.; Bjellerup, P.; Jacobsson, H.; Holst, J. J.; Hellström, P. M. GLP-1 inhibits gastric emptying of water but does not influence plasma vasopressin, sodium, or osmolality. Scand J Gastroenterol, 2001, 36, 156-162.
-
(2001)
Scand J Gastroenterol
, vol.36
, pp. 156-162
-
-
Näslund, E.1
Bogefors, J.2
Grybäck, P.3
Bjellerup, P.4
Jacobsson, H.5
Holst, J.J.6
Hellström, P.M.7
-
41
-
-
0032871230
-
GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
-
Näslund, E.; Bogefors, J.; Skogar, S.; Grybäck, P.; Jacobsson, H.; Holst, J. J.; Hellström, P. M. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am. J Physiol. 1999, 277, R910-916.
-
(1999)
Am. J Physiol.
, vol.277
-
-
Näslund, E.1
Bogefors, J.2
Skogar, S.3
Grybäck, P.4
Jacobsson, H.5
Holst, J.J.6
Hellström, P.M.7
-
42
-
-
0031695395
-
Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men
-
Nl̈und, E.; Gutniak, M.; Skogar, S.; Rössner, S.; Hellström, P. M. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am. J Clin. Nutr. 1998, 68, 525-530.
-
(1998)
Am. J Clin. Nutr.
, vol.68
, pp. 525-530
-
-
Nl̈und, E.1
Gutniak, M.2
Skogar, S.3
Rössner, S.4
Hellström, P.M.5
-
43
-
-
0030667056
-
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
-
Nauck, M. A.; Niedereichholz, U.; Ettler, R.; Holst, J. J.; Orskov, C.; Ritzel, R.; Schiniegel, W. H. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 1997, 273, E981-988.
-
(1997)
Am. J. Physiol.
, vol.273
-
-
Nauck, M.A.1
Niedereichholz, U.2
Ettler, R.3
Holst, J.J.4
Orskov, C.5
Ritzel, R.6
Schiniegel, W.H.7
-
44
-
-
19344375318
-
Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats
-
Chelikani, P. K.; Haver, A. C.; Reidelberger, R. D. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am. J. Physiol 2005, 288(6, Pt. 2), R1695-R1706.
-
(2005)
Am. J. Physiol
, vol.288
, Issue.6 PART 2
-
-
Chelikani, P.K.1
Haver, A.C.2
Reidelberger, R.D.3
-
45
-
-
15944419821
-
Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility
-
Miki, T.; Minami, K.; Shinozaki, H.; Matsumura, K.; Saraya, A.; Ikeda, H.; Yamada, Y.; Holst, J. J.; Scino, S. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 2005, 54, 1056-1063.
-
(2005)
Diabetes
, vol.54
, pp. 1056-1063
-
-
Miki, T.1
Minami, K.2
Shinozaki, H.3
Matsumura, K.4
Saraya, A.5
Ikeda, H.6
Yamada, Y.7
Holst, J.J.8
Scino, S.9
-
46
-
-
0037098976
-
GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat
-
Bozkurt, A.; Nälund, E.; Holst, J. I.; Hellström, P. M. GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat. Regul. Pept. 2002, 107, 129-135.
-
(2002)
Regul. Pept.
, vol.107
, pp. 129-135
-
-
Bozkurt, A.1
Nälund, E.2
Holst, J.I.3
Hellström, P.M.4
-
47
-
-
0035795230
-
The inhibitory mechanism of GLP-1, but not glucagon, on fasted gut motility is dependent on the L-arginine/nitric oxide pathway
-
Tolessa, T.; Nälund, E.; Hellström, P. M. The inhibitory mechanism of GLP-1, but not glucagon, on fasted gut motility is dependent on the L-arginine/nitric oxide pathway. Regul. Pept. 2001, 98, 33-40.
-
(2001)
Regul. Pept.
, vol.98
, pp. 33-40
-
-
Tolessa, T.1
Nälund, E.2
Hellström, P.M.3
-
48
-
-
0029907680
-
Effects of subcutaneous glucagon-like peptide 1 GLP-1 7-36 amide in patients with NIDDM
-
Nauck, M. A.; Wollschläger, D.; Werner, J.; Holst, J. J.; Orskov, C.; Creutzfeldt, W.; Willms, B. Effects of subcutaneous glucagon-like peptide 1 GLP-1 7-36 amide in patients with NIDDM. Diabetologia 1996, 39, 1546-1553.
-
(1996)
Diabetologia
, vol.39
, pp. 1546-1553
-
-
Nauck, M.A.1
Wollschläger, D.2
Werner, J.3
Holst, J.J.4
Orskov, C.5
Creutzfeldt, W.6
Willms, B.7
-
49
-
-
0033021677
-
Energy intake and appetite are suppressed by glucagon-like peptide-1 GLP-1 in obese men
-
Nälund, E.; Barkeling, B.; King, N.; Gutniak, M.; Blundell, J. E.; Holst, J. J.; Rössner, S.; Hellström, P. M. Energy intake and appetite are suppressed by glucagon-like peptide-1 GLP-1 in obese men. Int. J. Obesity 1999, 23, 304-311.
-
(1999)
Int. J. Obesity
, vol.23
, pp. 304-311
-
-
Nälund, E.1
Barkeling, B.2
King, N.3
Gutniak, M.4
Blundell, J.E.5
Holst, J.J.6
Rössner, S.7
Hellström, P.M.8
-
50
-
-
0034951506
-
The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity
-
Flint, A.; Raben, A.; Ersboll, A. K.; Holst, J. J.; Astrup, A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int. J. Obesity 2001, 25, 781-792.
-
(2001)
Int. J. Obesity
, vol.25
, pp. 781-792
-
-
Flint, A.1
Raben, A.2
Ersboll, A.K.3
Holst, J.J.4
Astrup, A.5
-
51
-
-
1642271221
-
Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects
-
Nälund, E.; King, N.; Mansten, S.; Adner, N.; Holst, J. J.; Gutniak, M.; Hellström, P. M. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br. J. Nutr. 2004, 91, 439-446.
-
(2004)
Br. J. Nutr.
, vol.91
, pp. 439-446
-
-
Nälund, E.1
King, N.2
Mansten, S.3
Adner, N.4
Holst, J.J.5
Gutniak, M.6
Hellström, P.M.7
-
52
-
-
0037045845
-
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study
-
Zander, M.; Madsbad, S.; Madsen, J. L.; Hoist, J. J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359, 824-830.
-
(2002)
Lancet
, vol.359
, pp. 824-830
-
-
Zander, M.1
Madsbad, S.2
Madsen, J.L.3
Hoist, J.J.4
-
53
-
-
19344374606
-
Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men
-
Brennan, I. M.; Feltrin, K. L.; Horowitz, M.; Smout, A. J. P., M.; Meyer, J. H.; Wishart, J.; Feinle, B., C. Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men. Am. J. Physiol. 2005, 288, R1477-R1485.
-
(2005)
Am. J. Physiol.
, vol.288
-
-
Brennan, I.M.1
Feltrin, K.L.2
Horowitz, M.3
Smout, A.J.P.M.4
Meyer, J.H.5
Wishart, J.6
Feinle, B.C.7
-
54
-
-
4243638562
-
Motility of the small intestine
-
2 ed.; Lippincott, J. B.: Philadelphia
-
Hasler, W. L. Motility of the small intestine. Textbook of Gastroenterology; 2 ed.; Lippincott, J. B.: Philadelphia, 1995; pp. 207-233.
-
(1995)
Textbook of Gastroenterology
, pp. 207-233
-
-
Hasler, W.L.1
-
55
-
-
0037096140
-
Glucagon-like peptide-1 analogue LY315902: Effect on intestinal motility and release of insulin and somatostatin
-
Näslund, E.; Skogar, S.; Efendic, S.; Hellström, P. M. Glucagon-like peptide-1 analogue LY315902: Effect on intestinal motility and release of insulin and somatostatin. Regul. Pept. 2002, 106, 89-95.
-
(2002)
Regul. Pept.
, vol.106
, pp. 89-95
-
-
Näslund, E.1
Skogar, S.2
Efendic, S.3
Hellström, P.M.4
-
56
-
-
15044340837
-
The physiological role of GLP-1 in human: Incretin, ileal brake or more?
-
Schirra, J.; Göke, B. The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul. Pept. 2005, 128, 109-115.
-
(2005)
Regul. Pept.
, vol.128
, pp. 109-115
-
-
Schirra, J.1
Göke, B.2
-
57
-
-
1642395091
-
Gastric inhibitory polypeptide does not inhibit gastric emptying in humans
-
Meier, J. J.; Goetze, O.; Anstipp, J.; Hagemann, D.; Holst, J. J.; Schmidt, W. E.; Gallwitz, B.; Nauck, M. A. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am. J. Physiol. 2004, 286(4, Pt. 1), E621-E625.
-
(2004)
Am. J. Physiol.
, vol.286
, Issue.4 PART 1
-
-
Meier, J.J.1
Goetze, O.2
Anstipp, J.3
Hagemann, D.4
Holst, J.J.5
Schmidt, W.E.6
Gallwitz, B.7
Nauck, M.A.8
-
58
-
-
0035851852
-
Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1
-
Hellström, P. M.; Näslund, E. Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1. Physiol. Behav. 2001, 74, 735-741.
-
(2001)
Physiol. Behav.
, vol.74
, pp. 735-741
-
-
Hellström, P.M.1
Näslund, E.2
-
59
-
-
13344282056
-
A role for glucagon-like peptide-1 in the central regulation of feeding
-
Turton, M. D.; O'Shea, D.; Gunn, I.; Beak, S. A.; Edwards, C. M. B.; Meeran, K.; Choi, S. J.; Taylor, G. M.; Heath, M. M. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379, 69-72.
-
(1996)
Nature
, vol.379
, pp. 69-72
-
-
Turton, M.D.1
O'Shea, D.2
Gunn, I.3
Beak, S.A.4
Edwards, C.M.B.5
Meeran, K.6
Choi, S.J.7
Taylor, G.M.8
Heath, M.M.9
-
60
-
-
0029859220
-
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
-
Tang, C. M.; Larsen, P. J.; Goke, R.; Fink J. A.; Jessop, D. S.; Moller, M.; Sheikh, S. P. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am. J. Physiol. 1996, 271, R848-R856.
-
(1996)
Am. J. Physiol.
, vol.271
-
-
Tang, C.M.1
Larsen, P.J.2
Goke, R.3
Fink, J.A.4
Jessop, D.S.5
Moller, M.6
Sheikh, S.P.7
-
61
-
-
0031964636
-
Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats
-
Donahey, J. C. K.; Van, D., G.; Woods, S. C.; Seeley, R. J. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. Brain Res. 1998, 779, 75-83.
-
(1998)
Brain Res.
, vol.779
, pp. 75-83
-
-
Donahey, J.C.K.1
Van, D.G.2
Woods, S.C.3
Seeley, R.J.4
-
62
-
-
0034085701
-
Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats
-
de Fonseca, F. R.; Navarro, M.; Alvarez, E.; Roncero, I.; Chowen, J. A.; Maestre, O.; Gomez, R.; Munoz, R. M.; Eng, J.; Blazquez, E. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metab., Clin. Exp. 2000, 49, 709-717.
-
(2000)
Metab., Clin. Exp.
, vol.49
, pp. 709-717
-
-
de Fonseca, F.R.1
Navarro, M.2
Alvarez, E.3
Roncero, I.4
Chowen, J.A.5
Maestre, O.6
Gomez, R.7
Munoz, R.M.8
Eng, J.9
Blazquez, E.10
-
63
-
-
0032940582
-
Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat
-
Meeran, K.; O'Shea, D.; Mark, C.; Edwards, B.; Turton, M. D.; Heath, M. M.; Gunn, I.; Abusnana, S.; Rossi, M.; Small, C. J.; Goldstone, A. P.; Taylor, G. M.; Sunter, D.; Steere, J.; Choi, S. J.; Ghatei, M. A.; Bloom, S. R. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999, 140, 244-250.
-
(1999)
Endocrinology
, vol.140
, pp. 244-250
-
-
Meeran, K.1
O'Shea, D.2
Mark, C.3
Edwards, B.4
Turton, M.D.5
Heath, M.M.6
Gunn, I.7
Abusnana, S.8
Rossi, M.9
Small, C.J.10
Goldstone, A.P.11
Taylor, G.M.12
Sunter, D.13
Steere, J.14
Choi, S.J.15
Ghatei, M.A.16
Bloom, S.R.17
-
64
-
-
0035829625
-
An anorexic; lipid mediator regulated by feeding
-
de Fonseca, F. R.; Navarro, M.; Gómez, R.; Escuredo, L.; Nava, F.; Fu, J.; Murillo-Rodríguez, E.; Giuffrida, A.; LoVerme, J.; Gaetani, S.; Kathuria, S.; Gall, C.; Piomelli, D. An anorexic; lipid mediator regulated by feeding. Nature 2001, 414, 209-212.
-
(2001)
Nature
, vol.414
, pp. 209-212
-
-
de Fonseca, F.R.1
Navarro, M.2
Gómez, R.3
Escuredo, L.4
Nava, F.5
Fu, J.6
Murillo-Rodríguez, E.7
Giuffrida, A.8
LoVerme, J.9
Gaetani, S.10
Kathuria, S.11
Gall, C.12
Piomelli, D.13
-
65
-
-
18144381593
-
The inhibitory effects of peripheral administration of peptide YY (3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway
-
Abbott; C. R.; Monteiro, M.; Small, C. J.; Sajedi, A.; Smith, K. L.; Parkinson, J. R., C; Ghatei, M. A.; Bloom, S. R. The inhibitory effects of peripheral administration of peptide YY (3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 2005, 1044, 127-131.
-
(2005)
Brain Res.
, vol.1044
, pp. 127-131
-
-
Abbott, C.R.1
Monteiro, M.2
Small, C.J.3
Sajedi, A.4
Smith, K.L.5
Parkinson, J.R.C.6
Ghatei, M.A.7
Bloom, S.R.8
-
66
-
-
17944365214
-
A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on Ad Libitum energy intake in humans
-
Verdich, C.; Flint, A.; Gutzwiller, J. P.; Näslund, E.; Beglinger, C.; Hellström, P., M.; Long, S. J.; Morgan, L. M.; Hoist, J. J.; Astrup, A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on Ad Libitum energy intake in humans. J. Clin. Endocrinol. Metabol. 2001, 86, 4382-4389.
-
(2001)
J. Clin. Endocrinol. Metabol.
, vol.86
, pp. 4382-4389
-
-
Verdich, C.1
Flint, A.2
Gutzwiller, J.P.3
Näslund, E.4
Beglinger, C.5
Hellström, P.M.6
Long, S.J.7
Morgan, L.M.8
Hoist, J.J.9
Astrup, A.10
-
67
-
-
0002300343
-
Glucagon-like peptide-1: A potent regulator of food intake in humans
-
Gutzwiller, J. P.; Goke, B.; Drewe, J.; Hildebrand, P.; Ketterer, S.; Handschin, D.; Winterhalder, R.; Conen, D.; Beglinger, C. Glucagon-like peptide-1: A potent regulator of food intake in humans. Gut 1999, 44, 81-86.
-
(1999)
Gut
, vol.44
, pp. 81-86
-
-
Gutzwiller, J.P.1
Goke, B.2
Drewe, J.3
Hildebrand, P.4
Ketterer, S.5
Handschin, D.6
Winterhalder, R.7
Conen, D.8
Beglinger, C.9
-
68
-
-
0032966882
-
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
-
Gutzwiller, J. P.; Drewe, J.; Goke, B.; Schmidt, H.; Rohrer, B.; Lareida, J.; Beglinger, C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 1999, 276, R1541-R1544.
-
(1999)
Am. J. Physiol.
, vol.276
-
-
Gutzwiller, J.P.1
Drewe, J.2
Goke, B.3
Schmidt, H.4
Rohrer, B.5
Lareida, J.6
Beglinger, C.7
-
69
-
-
0032976939
-
Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
-
Toft-Nielsen, M. B.; Madsbad, S.; Hoist, J. J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999, 22, 1137-1143.
-
(1999)
Diabetes Care
, vol.22
, pp. 1137-1143
-
-
Toft-Nielsen, M.B.1
Madsbad, S.2
Hoist, J.J.3
-
70
-
-
0141669196
-
Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes
-
Meneilly, G. S.; Greig, N.; Tildesley, H.; Habener, J. F.; Egan, J. M.; Elahi, D. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 2003, 26, 2835-2841.
-
(2003)
Diabetes Care
, vol.26
, pp. 2835-2841
-
-
Meneilly, G.S.1
Greig, N.2
Tildesley, H.3
Habener, J.F.4
Egan, J.M.5
Elahi, D.6
-
71
-
-
22644444292
-
Effects of liraglutide NN2211, a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes
-
Feinglos, M. N.; Saad, M. F.; Pi-Sunyer, F. X.; An, B.; Santiago, O. Effects of liraglutide NN2211, a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet. Med. 2005, 22, 1016-1023.
-
(2005)
Diabet. Med.
, vol.22
, pp. 1016-1023
-
-
Feinglos, M.N.1
Saad, M.F.2
Pi-Sunyer, F.X.3
An, B.4
Santiago, O.5
-
72
-
-
3342984674
-
The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes
-
Harder, H.; Nielsen, L.; Tu, D. T., Thi; Astrup, A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004, 27, 1915-1921.
-
(2004)
Diabetes Care
, vol.27
, pp. 1915-1921
-
-
Harder, H.1
Nielsen, L.2
Tu, D.T.3
Thi4
Astrup, A.5
-
73
-
-
2542451393
-
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide NN2211: A 12-week, double-blind, randomized, controlled trial
-
Madsbad, S.; Schmitz, O.; Ranstam, J.; Jakobsen, G.; Matthews, D. R. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide NN2211: a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004, 27, 1335-1342.
-
(2004)
Diabetes Care
, vol.27
, pp. 1335-1342
-
-
Madsbad, S.1
Schmitz, O.2
Ranstam, J.3
Jakobsen, G.4
Matthews, D.R.5
-
74
-
-
2342599057
-
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide NN2211 markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes
-
Degn, K. B.; Juhl, C. B.; Sturis, J.; Jakobsen, G.; Brock, B.; Chandramouli, V.; Rungby, J.; Landau, B., R.; Schmitz, O. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide NN2211 markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004, 53, 1187-1194.
-
(2004)
Diabetes
, vol.53
, pp. 1187-1194
-
-
Degn, K.B.1
Juhl, C.B.2
Sturis, J.3
Jakobsen, G.4
Brock, B.5
Chandramouli, V.6
Rungby, J.7
Landau, B.R.8
Schmitz, O.9
-
75
-
-
3242787184
-
Glucagon-like peptide 1 (GLP-1) and eating
-
Gutzwiller, J. P.; Degen, L.; Heuss, L.; Beglinger, C. Glucagon-like peptide 1 (GLP-1) and eating. Physiol. Behav. 2004, 82, 17-19.
-
(2004)
Physiol. Behav.
, vol.82
, pp. 17-19
-
-
Gutzwiller, J.P.1
Degen, L.2
Heuss, L.3
Beglinger, C.4
-
76
-
-
2542479964
-
Minireview: Gut peptides regulating satiety
-
Druce, M. R.; Small, C. J.; Bloom, S. R. Minireview: Gut peptides regulating satiety. Endocrinology 2004, 145, 2660-2665.
-
(2004)
Endocrinology
, vol.145
, pp. 2660-2665
-
-
Druce, M.R.1
Small, C.J.2
Bloom, S.R.3
-
77
-
-
1942487860
-
Gastrointestinal Satiety Signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide
-
Stanley, S.; Wynne, K.; Bloom, S. Gastrointestinal Satiety Signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide. Am. J. Physiol. 2004, 286, G693-G697.
-
(2004)
Am. J. Physiol.
, vol.286
-
-
Stanley, S.1
Wynne, K.2
Bloom, S.3
-
78
-
-
0038363769
-
Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors
-
Holst, J. J. Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Adv. Exp. Med. Biol. 2003, 524, 263-279.
-
(2003)
Adv. Exp. Med. Biol.
, vol.524
, pp. 263-279
-
-
Holst, J.J.1
-
79
-
-
0037974604
-
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
-
Conarello, S. L.; Li, Z.; Ronan, J.; Roy, R. S.; Zhu, L.; Jiang, G.; Liu, F.; Woods, J.; Zycband, E.; Moller, D. E.; Thomberry, N. A.; Zhang, B. B. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 6825-6830.
-
(2003)
Proc. Natl. Acad. Sci. U. S. A.
, vol.100
, pp. 6825-6830
-
-
Conarello, S.L.1
Li, Z.2
Ronan, J.3
Roy, R.S.4
Zhu, L.5
Jiang, G.6
Liu, F.7
Woods, J.8
Zycband, E.9
Moller, D.E.10
Thomberry, N.A.11
Zhang, B.B.12
-
80
-
-
0036312876
-
Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats
-
Sudre, B.; Broqua, P.; White, R. B.; Ashworth, D.; Evans, D. M.; Haigh, R.; Junien, J. L.; Aubert, M. L. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 2002, 51, 1461-1469.
-
(2002)
Diabetes
, vol.51
, pp. 1461-1469
-
-
Sudre, B.1
Broqua, P.2
White, R.B.3
Ashworth, D.4
Evans, D.M.5
Haigh, R.6
Junien, J.L.7
Aubert, M.L.8
-
81
-
-
2442482515
-
Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes
-
Ahrén, B.; Landin, O., M.; Jansson, P. A.; Svensson, M.; Holmes, D.; Schweizer, A. Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2004, 89, 2078-2084.
-
(2004)
J. Clin. Endocrinol. Metab.
, vol.89
, pp. 2078-2084
-
-
Ahrén, B.1
Landin, O.M.2
Jansson, P.A.3
Svensson, M.4
Holmes, D.5
Schweizer, A.6
-
82
-
-
0036583164
-
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
-
Ahrén, B.; Simonsson, E.; Larsson, H.; Landin-Olsson, M.; Torgeirsson, H.; Jansson, P. A.; Sandqvist, M.; Bavenholm, P.; Efendic, S.; Eriksson, J. W.; Dickinson, S.; Holmes, D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002, 25, 869-875.
-
(2002)
Diabetes Care
, vol.25
, pp. 869-875
-
-
Ahrén, B.1
Simonsson, E.2
Larsson, H.3
Landin-Olsson, M.4
Torgeirsson, H.5
Jansson, P.A.6
Sandqvist, M.7
Bavenholm, P.8
Efendic, S.9
Eriksson, J.W.10
Dickinson, S.11
Holmes, D.12
-
83
-
-
27744540889
-
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response
-
Ristic, S.; Byiers, S.; Foley, J.; Holmes, D. improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response. Diabetes Obes. Metab. 2005, 7, 692-698.
-
(2005)
Diabetes Obes. Metab.
, vol.7
, pp. 692-698
-
-
Ristic, S.1
Byiers, S.2
Foley, J.3
Holmes, D.4
-
84
-
-
9444285818
-
Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
-
Ahrén, B.; Gomis, R.; Standl, E.; Mills, D.; Schweizer, A. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27, 2874-2880.
-
(2004)
Diabetes Care
, vol.27
, pp. 2874-2880
-
-
Ahrén, B.1
Gomis, R.2
Standl, E.3
Mills, D.4
Schweizer, A.5
-
85
-
-
0036231443
-
Gastric emptying in diabetes: Clinical significance and treatment
-
Horowitz, M.; O'Donovan, D.; Jones, K. L.; Feinle, C.; Rayner, C. K.; Samsom, M. Gastric emptying in diabetes: Clinical significance and treatment. Diabet. Med. 2002, 19, 177-194.
-
(2002)
Diabet. Med.
, vol.19
, pp. 177-194
-
-
Horowitz, M.1
O'Donovan, D.2
Jones, K.L.3
Feinle, C.4
Rayner, C.K.5
Samsom, M.6
-
86
-
-
0037370995
-
Glucagon-like peptide 2 function in domestic animals
-
Burrin, D. G.; Stoll, B.; Guan, X. Glucagon-like peptide 2 function in domestic animals. Domest. Anim. Endocrinol. 2003, 24, 103-122.
-
(2003)
Domest. Anim. Endocrinol.
, vol.24
, pp. 103-122
-
-
Burrin, D.G.1
Stoll, B.2
Guan, X.3
-
87
-
-
0035097144
-
Glucagon-like peptide 2: A nutrient-responsive gut growth factor
-
Burrin, D. G.; Petersen, Y.; Stoll, B.; Sangild, P. Glucagon-like peptide 2: A nutrient-responsive gut growth factor. J. Nutr. 2001, 131, 709-712.
-
(2001)
J. Nutr.
, vol.131
, pp. 709-712
-
-
Burrin, D.G.1
Petersen, Y.2
Stoll, B.3
Sangild, P.4
-
88
-
-
0037898380
-
Diabetic dyslipidaemia: From basic research to clinical practice
-
Taskinen, M. R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 733-749.
-
Diabetologia
, vol.2003
, pp. 733-749
-
-
Taskinen, M.R.1
-
89
-
-
0029741921
-
A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
-
Stampfer, M. J.; Krauss, R. M.; Ma, J.; Blanche, P. J.; Holl, L. G.; Sacks, F. M.; Hennekens, C. H. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996, 276, 882-888.
-
(1996)
JAMA
, vol.276
, pp. 882-888
-
-
Stampfer, M.J.1
Krauss, R.M.2
Ma, J.3
Blanche, P.J.4
Holl, L.G.5
Sacks, F.M.6
Hennekens, C.H.7
-
90
-
-
0035085298
-
Effect of GLP-1 on lipid metabolism in human adipocytes
-
Villanueva Peñcarrillo, M. L.; Márquez, L.; González, N.; Díaz, M. M.; Valverde, I. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm. Metab. Res. 2001, 33, 73-77.
-
(2001)
Horm. Metab. Res.
, vol.33
, pp. 73-77
-
-
Villanueva Peñcarrillo, M.L.1
Márquez, L.2
González, N.3
Díaz, M.M.4
Valverde, I.5
-
91
-
-
0033011692
-
Effect of gastric inhibitory polypeptide on bovine fat metabolism
-
Dawson, J. M.; Greathead, H. M. R.; Sessions, V. A.; Tye, F. M.; Buttery, P. J. Effect of gastric inhibitory polypeptide on bovine fat metabolism. Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol. 1999, 123, 79-88.
-
(1999)
Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol.
, vol.123
, pp. 79-88
-
-
Dawson, J.M.1
Greathead, H.M.R.2
Sessions, V.A.3
Tye, F.M.4
Buttery, P.J.5
-
92
-
-
0035153727
-
Glucagon-like peptide 1 stimulates lipolysis in clonal pancreatic (beta)-cells (HIT)
-
Yaney, G. C.; Civelek, V. N.; Richard, A. M.; Dillon, J. S.; Deeney, J. T.; Hamilton, J., A.; Korchak, H. M.; Tornheim, K.; Corkey, B. E.; Boyd, I., Aubrey, E., III. Glucagon-like peptide 1 stimulates lipolysis in clonal pancreatic (beta)-cells (HIT). Diabetes 2001, 50, 56-62.
-
(2001)
Diabetes
, vol.50
, pp. 56-62
-
-
Yaney, G.C.1
Civelek, V.N.2
Richard, A.M.3
Dillon, J.S.4
Deeney, J.T.5
Hamilton, J.A.6
Korchak, H.M.7
Tornheim, K.8
Corkey, B.E.9
Boyd, I.10
Aubrey III, E.11
-
93
-
-
0142074274
-
GLP-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation during cell differentiation and insulin release
-
Bulotta, A.; Perfetti, R.; Hui, H.; Boros, L. G. GLP-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation during cell differentiation and insulin release. J. Lipid Res. 2003, 44, 1559-1565.
-
(2003)
J. Lipid Res.
, vol.44
, pp. 1559-1565
-
-
Bulotta, A.1
Perfetti, R.2
Hui, H.3
Boros, L.G.4
-
94
-
-
23844526330
-
Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats
-
Sancho, V.; Trigo, M. V.; González, N.; Valverde, I.; Malaisse, W. J.; Villanueva Peñacarrillo, M. L. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J. Mol. Endocrinol. 2005, 35, 27-38.
-
(2005)
J. Mol. Endocrinol.
, vol.35
, pp. 27-38
-
-
Sancho, V.1
Trigo, M.V.2
González, N.3
Valverde, I.4
Malaisse, W.J.5
Villanueva Peñacarrillo, M.L.6
-
95
-
-
0034011021
-
The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans
-
Flint, A.; Raben, A.; Rehfeld, J. F.; Holst, J. J.; Astrup, A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int. J. Obesity 2000, 24, 288-298.
-
(2000)
Int. J. Obesity
, vol.24
, pp. 288-298
-
-
Flint, A.1
Raben, A.2
Rehfeld, J.F.3
Holst, J.J.4
Astrup, A.5
-
96
-
-
0027157849
-
Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable
-
Orskov, C.; Wettergren, A.; Holst, J. J. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993, 42, 658-661.
-
(1993)
Diabetes
, vol.42
, pp. 658-661
-
-
Orskov, C.1
Wettergren, A.2
Holst, J.J.3
-
97
-
-
17644373076
-
GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats
-
Qin, X.; Shen, H.; Liu, M.; Yang, Q.; Zheng, S.; Sabo, M.; D'Alessio, D. A.; Tso, P. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am. J. Physiol. 2005, 288, G943-G949.
-
(2005)
Am. J. Physiol.
, vol.288
-
-
Qin, X.1
Shen, H.2
Liu, M.3
Yang, Q.4
Zheng, S.5
Sabo, M.6
D'Alessio, D.A.7
Tso, P.8
-
98
-
-
0029857454
-
The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients
-
Juntti, B. L.; Pigon, J.; Karpe, F.; Hamsten, A.; Gutniak, M.; Vignati, L.; Efendic, S. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 1996, 19, 1200-1206.
-
(1996)
Diabetes Care
, vol.19
, pp. 1200-1206
-
-
Juntti, B.L.1
Pigon, J.2
Karpe, F.3
Hamsten, A.4
Gutniak, M.5
Vignati, L.6
Efendic, S.7
-
99
-
-
3342971029
-
Additive effects of glucagon-fike peptide 1 and pioglitazone in patients with type 2 diabetes
-
Zander, M.; Christiansen, A.; Madsbad, S.; Holst, J. J. Additive effects of glucagon-fike peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care 2004, 27, 1910-1914.
-
(2004)
Diabetes Care
, vol.27
, pp. 1910-1914
-
-
Zander, M.1
Christiansen, A.2
Madsbad, S.3
Holst, J.J.4
-
100
-
-
0018672563
-
Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes
-
Eckel, R. H.; Fujimoto, W. Y.; Brunzell, J. D. Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes 1979, 28, 1141-1142.
-
(1979)
Diabetes
, vol.28
, pp. 1141-1142
-
-
Eckel, R.H.1
Fujimoto, W.Y.2
Brunzell, J.D.3
-
101
-
-
0031730586
-
Functional GIP receptors are present on adipocytes
-
Yip, R. G. C.; Boylan, M. O.; Kieffer, T. J.; Wolfe, M. M. Functional GIP receptors are present on adipocytes. Endocrinology 1998, 139, 4004-4007.
-
(1998)
Endocrinology
, vol.139
, pp. 4004-4007
-
-
Yip, R.G.C.1
Boylan, M.O.2
Kieffer, T.J.3
Wolfe, M.M.4
-
102
-
-
0032895556
-
Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: Wortmannin-sensitive inhibition by insulin
-
McIntosh, C. H. S.; Bremsak, I.; Lynn, F. C.; Gill, R.; Hinke, S. A.; Gelling, R.; Nian, C.; McKnight, G.; Jaspers, S.; Pederson, R. A. Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: Wortmannin-sensitive inhibition by insulin. Endocrinology 1999, 140, 398-404.
-
(1999)
Endocrinology
, vol.140
, pp. 398-404
-
-
McIntosh, C.H.S.1
Bremsak, I.2
Lynn, F.C.3
Gill, R.4
Hinke, S.A.5
Gelling, R.6
Nian, C.7
McKnight, G.8
Jaspers, S.9
Pederson, R.A.10
-
103
-
-
0033817531
-
Effects of gastric inhibitory polypeptide, somatostatin and epidermal growth factor on lipogenesis in ovine adipose explants
-
Baba, A. S. H.; Harper, J. M. M.; Buttery, P. J. Effects of gastric inhibitory polypeptide, somatostatin and epidermal growth factor on lipogenesis in ovine adipose explants. Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol. 2000, 127, 173-182.
-
(2000)
Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol.
, vol.127
, pp. 173-182
-
-
Baba, A.S.H.1
Harper, J.M.M.2
Buttery, P.J.3
-
104
-
-
0024271044
-
Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes
-
Hauner, H.; Glatting, G.; Kaminska, D.; Pfeiffer, E. F. Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes. Ann. Nutr. Metab. 1988, 32, 282-288.
-
(1988)
Ann. Nutr. Metab.
, vol.32
, pp. 282-288
-
-
Hauner, H.1
Glatting, G.2
Kaminska, D.3
Pfeiffer, E.F.4
-
105
-
-
0026534074
-
Effects of gastro-entero-pancreatic hormones upon triglyceride synthesis and secretion by rat hepatocytes
-
Wolfe, B. M. Effects of gastro-entero-pancreatic hormones upon triglyceride synthesis and secretion by rat hepatocytes. Clin. Invest. Med. 1992, 15, 30-41.
-
(1992)
Clin. Invest. Med.
, vol.15
, pp. 30-41
-
-
Wolfe, B.M.1
-
106
-
-
0025750777
-
Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats
-
Ebert, R.; Nauck, M.; Creutzfeldt, W. Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats. Horm. Metab. Res. 1991, 23, 517-521.
-
(1991)
Horm. Metab. Res.
, vol.23
, pp. 517-521
-
-
Ebert, R.1
Nauck, M.2
Creutzfeldt, W.3
-
107
-
-
0019407932
-
Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs
-
Wasada, T.; McCorkle, K.; Harris, V. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J. Clin. Invest. 1981, 68, 1106-1107.
-
(1981)
J. Clin. Invest.
, vol.68
, pp. 1106-1107
-
-
Wasada, T.1
McCorkle, K.2
Harris, V.3
|